Labs-on-a-chip for early drug assessment
- Control of R&D costs
- Impact of R&D strategy
- Real-time & kinetic capture of secretion of biomarkers
- Incorporated startups
90% of new drugs fail clinical trials on humans, which results in substantial financial losses for the pharmaceutical industry. This is mainly due to inadequate assessment during the early phases of R&D through the lack of predictive tests for effects on humans.
Based on microfluidics, the Nanobiose lab-on-a-chip integrates 3D cell culture technologies (imitating physiological conditions more effectively) and a removable biosensor that enables the multiplex analysis of biomarkers (up to 9) by measuring fluorescence.
- Combination in a single experiment of 3D cell culture
- Real-time capture of biomarkers secreted by the cells
- Unique results (the kinetics of the biomarkers)
- Significant saving in man-hours (< 50%)
State of progress
The POC was created with the support of BPI and thanks to a FrenchTech Emergence grant. Lab-on-a-chip prototypes and biosensors (5 cytokines tested) were produced and are currently used to develop a first application concerning a 3D model for the inflammation of human macrophages.
SecretCells® also enables researchers to assess the potential effects of their candidate drugs more rapidly and efficiently by creating a direct link between potential toxicity and efficacy.